ASPHF'
s Pretax Margin % Range Over the Past 10 Years
Min: -10213.93 Med: -1652.33 Max: -40.31
Current: -215.14
ASPHF's Pretax Margin % is ranked worse than 61.14% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs ASPHF: -215.14
Ascentage Pharma Group International (OTCPK:ASPHF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ascentage Pharma Group International Pretax Margin % Related Terms
Ascentage Pharma Group International Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Pretax Margin % Chart
ASPHF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Pretax Margin % of -191.16% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #579 out of 947 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Ascentage Pharma Group International's Pretax Margin % too high?
Ascentage Pharma Group International's current Pretax Margin % is -191.16%. Based on the distribution chart, Ascentage Pharma Group International ranks #579 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #579 out of 947 companies for Pretax Margin %. This places Ascentage Pharma Group International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ascentage Pharma Group International and its competitors. Ascentage Pharma Group International's current Pretax Margin % is -191.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Pretax Margin % is -191.16%. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Pretax Margin % is -191.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Pretax Margin %: -191.16%
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
